MARLINA-T2D trial demonstrates Tradjenta (linagliptin) offers benefits in blood glucose for type 2 diabetes- Boehringer/Eli Lilly

Results from the MARLINA-T2D trial demonstrated that Tradjenta (linagliptin), from Boehringer and Eli Lilly, reduced blood sugar in adults with type 2 diabetes (T2D) who are at risk for kidney impairment, with a renal safety profile similar to that seen in other trials. MARLINA-T2D examined the safety and efficacy of Tradjenta versus placebo in 360 patients with T2D and albuminuria (defined as urinary albumin-to-creatinine ratio (UACR) 30-3000 mg/g creatinine).

At 24 weeks, Tradjenta was associated with a significant 0.6 percent reduction in A1C (a measure of average blood glucose over the past two to three months) versus placebo. Change in albuminuria, as measured by UACR, was non-significant with Tradjenta versus placebo. Tradjenta was well tolerated in the trial, with a renal safety profile consistent with that of previous clinical trials. The findings will be presented at the American Diabetes Association 76th Scientific Sessions.